XBiotech Inc. (XBIT) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
XBiotech Inc. is a pre-market biopharmaceutical company incorporated in British Columbia, Canada, with principal executive offices in Austin, Texas. The company develops "True Human" monoclonal antibodies derived from natural human immune responses, focusing on inflammatory and infectious diseases. This filing covers the fiscal year ended December 31, 2025. The company is classified as a non-accelerated filer and a smaller reporting company. As of December 31, 2025, the company had 85 full-time employees.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(45,540) | $(38,531) |
| Operating Expenses | $55,685 | $42,471 |
| Research & Development (R&D) | $47,390 | $37,757 |
| General & Administrative (G&A) | $8,295 | $4,714 |
| Cash and Cash Equivalents (End of Period) | $125,551 | $172,677 |
| Net Cash Used in Operating Activities | $(39,920) | $(30,963) |
| Total Assets | $150,082 | $199,093 |
| Total Liabilities | $9,732 | $16,825 |
| Accumulated Deficit | $(136,377) | $(90,837) |
Debt and Liquidity: The company had no long-term debt as of December 31, 2025. A $10 million convertible loan from a related party (John Simard) was fully repaid in January 2025. The company maintains a strong liquidity position with approximately $125.6 million in cash, which management believes is sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $7.0 million (18%) from 2024 to 2025, driven primarily by higher operating expenses.
- R&D Expenses: Increased by 26% to $47.4 million. This was largely due to a $17.3 million severance payment and a $4.5 million annual bonus for former CEO John Simard (85% allocated to R&D), as well as increased share-based compensation.
- G&A Expenses: Increased by 76% to $8.3 million, also driven by the Simard severance and bonus (15% allocated to G&A) and increased share-based compensation.
- Cash Position: Cash and cash equivalents decreased by $47.1 million, primarily due to operating losses and the repayment of the $10 million related-party loan.
- Other Income: Total other income increased to $10.4 million in 2025 from $3.9 million in 2024, largely due to a $3.3 million foreign exchange gain and $1.5 million in other income (including Employee Retention Credits).
Guidance, Outlook, and Risks
Outlook: Management does not expect to generate any revenue in fiscal year 2026. The company anticipates continuing to incur significant operating losses as it advances drug candidates through clinical development. No dividends are expected in the foreseeable future.
Management Commentary:
- Leadership Change: Founder and former CEO John Simard retired on December 8, 2025. Dr. Sushma Shivaswamy serves as Interim CEO and Chief Scientific Officer.
- Clinical Pipeline:
- Natrunix (Oncology): Preliminary data from a pancreatic cancer study (completed April 2025) showed reduced hospitalization and fewer adverse events. The company is discussing the regulatory path with the FDA.
- Natrunix (Rheumatology): A Phase II study for rheumatoid arthritis was completed in late 2024, but data was deemed uninterpretable due to widespread enrollment irregularities and improprieties at clinical sites. The program is paused pending further investigation.
- Hutrukin (Neurology): Phase I stroke study completed in late 2023. Phase II launch is on hold pending clarification of regulatory paths for the oncology and arthritis programs.
Risks and Contingencies:
- Profitability: The company has no approved products and no product revenue. It may never achieve profitability.
- Clinical Trial Risks: Future trials may fail, or regulatory approval may be delayed or denied. The recent rheumatology trial failure highlights risks related to clinical site management.
- Capital Requirements: While current cash is sufficient for 12+ months, significant additional capital will be required for future development and commercialization.
- Key Personnel: The departure of the founder/CEO introduces execution risk, though he remains Chairman and a consultant.
Key Facts for Investor Verification
- Cash Runway: Verify the $125.6 million cash balance and the management assertion that it funds operations for at least 12 months given the burn rate of ~$40 million/year.
- Rheumatology Trial Data: Investigate the specific nature of the "enrollment irregularities" that rendered the Natrunix rheumatology data uninterpretable and the company's plan to address this.
- Severance Impact: Confirm that the $21.8 million in total compensation (severance + bonus) for John Simard was a one-time event and will not recur in future periods.
- Regulatory Strategy: Monitor FDA communications regarding the regulatory path for Natrunix in oncology, as this is the primary near-term catalyst.
- Debt Status: Confirm the full repayment of the $10 million related-party loan and the absence of other significant debt obligations.